- Home
- GCTS vs HOWL Comparison
GCTS vs HOWL Comparison
Compare GCTS & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTS
- HOWL
- Stock Information
- Founded
- GCTS 1998
- HOWL 2017
- Country
- GCTS United States
- HOWL United States
- Employees
- GCTS N/A
- HOWL N/A
- Industry
- GCTS Blank Checks
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- GCTS Finance
- HOWL Health Care
- Exchange
- GCTS Nasdaq
- HOWL Nasdaq
- Market Cap
- GCTS 73.7M
- HOWL 64.5M
- IPO Year
- GCTS N/A
- HOWL 2021
- Fundamental
- Price
- GCTS $1.62
- HOWL $1.46
- Analyst Decision
- GCTS Strong Buy
- HOWL Strong Buy
- Analyst Count
- GCTS 1
- HOWL 5
- Target Price
- GCTS $5.00
- HOWL $7.20
- AVG Volume (30 Days)
- GCTS 260.1K
- HOWL 148.8K
- Earning Date
- GCTS 11-13-2025
- HOWL 11-06-2025
- Dividend Yield
- GCTS N/A
- HOWL N/A
- EPS Growth
- GCTS N/A
- HOWL N/A
- EPS
- GCTS N/A
- HOWL N/A
- Revenue
- GCTS $6,073,000.00
- HOWL N/A
- Revenue This Year
- GCTS $133.55
- HOWL N/A
- Revenue Next Year
- GCTS $347.37
- HOWL N/A
- P/E Ratio
- GCTS N/A
- HOWL N/A
- Revenue Growth
- GCTS N/A
- HOWL N/A
- 52 Week Low
- GCTS $0.90
- HOWL $0.60
- 52 Week High
- GCTS $3.45
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- GCTS 69.51
- HOWL 64.53
- Support Level
- GCTS $1.26
- HOWL $1.38
- Resistance Level
- GCTS $1.59
- HOWL $1.47
- Average True Range (ATR)
- GCTS 0.07
- HOWL 0.07
- MACD
- GCTS 0.03
- HOWL 0.01
- Stochastic Oscillator
- GCTS 96.10
- HOWL 85.00
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.